Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Cann Group ( (AU:CAN) ).
Cann Group Limited has received a second advance of $315,552 from Radium Capital, providing early access to its expected R&D Tax Incentive for FY2025. This funding, along with a previous advance, totals $1,152,021 and will be repaid upon receipt of the R&D rebate or by 31 October 2025. This financial maneuver supports Cann Group’s ongoing R&D activities, potentially strengthening its position in the cannabis industry by ensuring continuous innovation and product development.
More about Cann Group
Cann Group Limited is a company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. It operates research facilities and a large-scale cultivation and GMP manufacturing facility in Victoria, Australia. The company offers a range of dried flower and oil products, active pharmaceutical ingredients, and extracts to customers globally. Cann Group also owns Satipharm and its patent-protected capsule technology.
YTD Price Performance: -66.67%
Average Trading Volume: 1,935,771
Technical Sentiment Signal: Sell
Current Market Cap: A$8.27M
Find detailed analytics on CAN stock on TipRanks’ Stock Analysis page.